Literature DB >> 31101214

Diagnosis and Management of a De Novo Urothelial Carcinoma in a Kidney Allograft: A Case Report.

Ádám Z Farkas1, Szilárd Török2, János Balázs Kovács2, László Piros2, Gyula Végső2, Gergely Kiss2, Dávid Korda2, András Bibok2, Erika Hartmann2, Ákos P Deák2, Attila Doros2.   

Abstract

INTRODUCTION: Following renal transplantation, the incidence of malignancies is 3-5 times higher than that of healthy individuals. Among other type of cancers, the risk of urological tumors is also elevated. However, only a few cases of de novo transitional cell carcinomas occurring in renal allografts have been reported. CASE REPORT: A 63-year-old tertiary transplanted male patient was urgently hospitalized for a painless macroscopic hematuria. Ultrasonography revealed pyelectasis and a hematoma in the renal pelvis. A percutaneous nephrostomy tube was inserted. An anterograde pyelography was performed later, where a filling defect was still observable in the location of the previously reported hypoechoic mass. Contrast-enhanced ultrasonography showed enhancement of the lesion. An ultrasound-guided percutaneous biopsy was performed. The histologic evaluation revealed a high-grade transitional cell carcinoma. A whole-body staging computed tomography scan did not show signs of metastatic disease. The renal allograft was surgically removed. No disease progression was observed during the 21-month follow-up period.
CONCLUSIONS: Painless hematuria and asymptomatic hydronephrosis occurring after kidney transplantation should raise the possibility of urothelial carcinoma in the kidney graft. Contrast-enhanced ultrasound should be considered as a first-line diagnostic modality because it is easily accessible and does not raise concerns about nephrotoxicity or radiation burden.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2019        PMID: 31101214     DOI: 10.1016/j.transproceed.2019.04.011

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  1 in total

1.  Complete response to pembrolizumab for metastatic urothelial carcinoma in the renal pelvis of allograft kidney.

Authors:  Jun Kamei; Hirotaka Yokoyama; Toshiro Niki; Ryosuke Suda; Toru Sugihara; Akira Fujisaki; Satoshi Ando; Daiki Iwami; Tetsuya Fujimura
Journal:  IJU Case Rep       Date:  2022-03-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.